《中国期刊全文数据库》收录期刊
《中国核心期刊（遴选）数据库》收录期刊
《中文科技期刊数据库》收录期刊
外科研究与新技术（中英文）

外科研究与新技术（中英文） >

2023 , Vol. 12 >Issue 3: 157 - 162

DOI: https://doi.org/10.3969/j.issn.2095-378X.2023.03.001

述评

肝细胞癌合并门静脉癌栓诊治新进展

  • 楼振邦 ,
  • 王康 ,
  • 程玉强 ,
  • 禹鸿鸣 ,
  • 程树群
展开
  • 1.广东药科大学第一临床医学院, 广东 广州 510006;
    2.东方肝胆外科医院肝外六科, 上海 200433
楼振邦（1997—）,男,硕士研究生,住院医师,从事临床肝胆外科工作

收稿日期: 2023-08-08

  网络出版日期: 2023-10-24

基金资助

上海市重中之重研究项目（2023ZZ02005）; 国家自然科学基金重点项目（82072618）; 国家科技部重点研发项目（2022YFC2503700）

收起

New progression in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis

  • LOU Zhenbang ,
  • WANG Kang ,
  • CHENG Yuqiang ,
  • YU Hongming ,
  • CHENG Shuqun
Expand
  • 1. The First clinical Medicine School of Guandong Pharmaceutical University ,Guangzhou 510006,Guangdong, China;
    2. Department of Hepatic Ⅵ, Eastern Hepatobiliary Surgery Hospital, Shanghai 200433, China

Received date: 2023-08-08

  Online published: 2023-10-24

Fold

摘要

门静脉癌栓是中晚期肝细胞癌（以下简称肝癌）的典型临床表现,也是预后不良的主要原因。近年来,随着靶免药物的相继入世,肝癌合并门静脉癌栓诊治理念和诊治策略都有了较大改变,如门静脉癌栓的分型分期,多学科诊治的流程,以及综合治疗的组合等。

关键词： 肝细胞癌; 门静脉癌栓; 刘程分期; 多学科综合诊疗

本文引用格式

楼振邦 , 王康 , 程玉强 , 禹鸿鸣 , 程树群 . 肝细胞癌合并门静脉癌栓诊治新进展[J]. 外科研究与新技术（中英文）, 2023 , 12(3) : 157 -162 . DOI: 10.3969/j.issn.2095-378X.2023.03.001

Abstract

Portal vein tumor thrombus is a typical clinical manifestation of advanced hepatocellular carcinoma（HCC）, and it is also the main cause of death. In recent years, the idea and strategy of diagnosis and treatment of HCC complicated with portal vein tumor thrombosis have changed greatly with the successive use of targeted therapy and immunotherapy, such as the classification and staging of portal vein tumor thrombus, the process of multidisciplinary diagnosis and treatment, and the combination of comprehensive treatment.

Key words： Hepatocellular carcinoma; Portal vein tumor thrombosis; Lau-Cheng stage system; Multidisciplinary diagnosis and treatment

参考文献

[1] Ferlay J, Colombet M, Soerjomataram I, et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953.
[2] Llovet JM, Kelley RK,Villanueva A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[3] Katagiri S, Yamamoto M.Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J].Surg Today, 2014, 44(2): 219-226.
[4] Cheng SQ, Wu MC, Chen H, et al.Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54(74): 499-502.
[5] Kudo M, Izumi N, Kubo S, et al.Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2020, 50(1): 15-46.
[6] Lau WY,Wang K, Zhang XP,et al.A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus[J]. Hepatobiliary Surg Nutr,2021, 10(6): 782-795.
[7] Sun J,Guo R, Bi X, et al.Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition)[J]. Liver Cancer, 2022, 11(4): 315-328.
[8] EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[9] Chen ZH,Zhang XP, Zhou T, et al.Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(11): 2188-2196.
[10] Zhang XP, Chai ZT, Gao Y Z, et al.Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB (Oxford), 2019, 21(12): 1687-1696.
[11] Wei X, Jiang Y, Zhang X, et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol 2019, 37(24): 2141-2151.
[12] Zhang YF, Guo RP, Zou RH, et al.Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol 2016, 26(7): 2078-88.
[13] Li S, Zhong C, Li Q, et al.Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2021. 39(15): 4008.
[14] Zhang X, Wang K, Wang M, et al.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427.
[15] Fu Z, Li X, Zhong J, et al.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
[16] Li XL, Guo WX, Hong XD, et al.Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis[J]. Hepatol Res, 2016, 46(11):1088-1098.
[17] Guo L, Wei X, Feng S, et al.Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial[J]. Hepatol Int, 2022, 16(6):1368-1378.
[18] Feng JK, Liu Z H, Fu Z G, et al.Efficacy and safety of transarterial chemoembolization plus antiangiogenic-targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world[J]. Front Oncol, 2022, 25(12): 954203.
[19] Zhang W, Zhang K, Liu C, et al.Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study[J]. Front Immunol, 2023, 26(14): 1127349.
[20] Luo L, Xiao Y, Zhu G, et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience[J]. Front Oncol, 2022,23(12): 1004652.
[21] Yang X, Chen B, Wang Y, et al.Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients[J]. Hepatol Int, 2023, 17(3): 709-719.
[22] Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[23] Wang K, Xiang YJ, Yu HM, et al.Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study[J]. Front Immunol, 2023, 16(14): 1107542.
[24] Sun J, Liu C, Shi J, et al.A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study[J]. Chin Med J (Engl), 2022, 135(19): 2338-2343.
Options
文章导航

/

〈 〉